Cancer Not Just “Bad Luck”

A new study refutes one published earlier this year that claimed random mutations were at the root of many tumors.

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

FLICKR, USAG HUMPHREYSOnly 10 to 30 percent of cancer cases can be attributed to random mutations in DNA, according to a study published this week (December16) in Nature. Rather, the majority of cancer cases stem from carcinogens such as toxic chemicals and radiation, the researchers found.

The results challenge those of a January Science study, which found that cell division and random mutations in DNA play a principal role in the development of cancer. A press release and many media outlets distributed the story, stating that some tissues’ higher rates of cancer are simply due to “bad luck”—meaning that avoiding things like the sun and cigarettes would not stem many instances of cancer.

“There’s no question what’s at stake here,” John Potter of the Fred Hutchinson Cancer Research Center in Seattle, Washington, who was not involved in which study told Nature. “This informs whether or not we expend energy on prevention.”

After the Science paper was published earlier this year, cancer researcher Yusuf Hannun of Stony Brook University in New York ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Jef Akst

    Jef Akst was managing editor of The Scientist, where she started as an intern in 2009 after receiving a master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide